PMID: 9660990Jul 14, 1998Paper

Pharmacokinetic evaluation of amphotericin B in lung tissue: lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B

Antimicrobial Agents and Chemotherapy
T KoizumiM Sekiguchi

Abstract

We have studied the pharmacokinetics of amphotericin B (AmB) in lung lymph circulation and bronchial-wash fluid after intravenous infusion and inhalation, respectively. For two experiments with awake sheep, we used lung lymph fistulas and tracheotomy. In experiment 1, AmB concentrations in plasma and lung lymph after intravenous infusion of AmB (1 mg/kg of body weight) over 1.5 h were measured. The mean peak in plasma level was 756.0 +/- 188.8 ng/ml at 3 h after the start of infusion, and the level then decreased gradually to 194.8 +/- 28.9 ng/ml at 24 h. The stable and maximal levels in lung lymph last 5 to 9 h after the start of AmB infusion. The concentrations in lung lymph after 9 h were slightly higher than those in plasma. Thus, the lung lymph-to-plasma ratio of AmB concentrations increased gradually during infusion, and the ratio was more than 1.0 after the end of infusion, suggesting that AmB could be easily moved from plasma to pulmonary interstitium and/or lung lymph circulation. In another experiment, 5 or 30 mg of aerosol AmB was inhaled, and the concentration of AmB in the bronchial-wash fluid was determined by bronchoalveolar lavage. The peak AmB concentration in the fluid was observed at 0.5 h. After that, AmB wa...Continue Reading

References

Aug 1, 1979·Circulation Research·K L BrighamJ Haynes
Nov 11, 1975·The Journal of Surgical Research·N C StaubW C Woolverton
Aug 1, 1992·Journal of Applied Physiology·T KoizumiM Sekiguchi
Jan 1, 1990·Antimicrobial Agents and Chemotherapy·Y NikiD Armstrong
Apr 1, 1989·Journal of Pharmaceutical Sciences·G G ChabotL H Baker
Oct 1, 1988·The Journal of Clinical Investigation·J P Wiener-KronishN C Staub
Jan 1, 1988·Journal of Applied Physiology·V C BroaddusN C Staub
May 1, 1988·Journal of Applied Physiology·J H NewmanR J Roselli
Jan 3, 1974·The New England Journal of Medicine·J E Bennett
Oct 1, 1969·The Journal of Infectious Diseases·D D Bindschadler, J E Bennett
Jun 1, 1970·Applied Microbiology·B T FieldsR S Abernathy
Jun 1, 1984·The Journal of Infectious Diseases·J BrajtburgG Medoff
Jan 17, 1980·The New England Journal of Medicine·G Medoff, G S Kobayashi
Jun 1, 1993·Antimicrobial Agents and Chemotherapy·J BeyerW Siegert
Apr 1, 1993·Japanese Journal of Cancer Research : Gann·T KoizumiR Sakai

❮ Previous
Next ❯

Citations

Jun 28, 2005·Antimicrobial Agents and Chemotherapy·Joan GavaldàAlbert Pahissa
Sep 29, 2006·Antimicrobial Agents and Chemotherapy·Andreas H GrollThomas J Walsh
Sep 20, 2007·Expert Opinion on Drug Safety·Stephanie A Knechtel, Michael E Klepser
Sep 25, 2003·Antimicrobial Agents and Chemotherapy·Michail S LionakisDimitrios P Kontoyiannis
May 27, 2010·Current Fungal Infection Reports·Jennifer Le, Daryl S Schiller
Jul 31, 2009·Drug Development and Industrial Pharmacy·Justin A Tolman, Robert O Williams
Jun 23, 2009·Expert Opinion on Drug Safety·Amar SafdarBurton F Dickey
Jan 18, 2005·Clinical Microbiology Reviews·Nina Singh, David L Paterson
Jan 8, 2014·Clinical Microbiology Reviews·Timothy FeltonWilliam W Hope
Jan 31, 2002·The Annals of Pharmacotherapy·Michael E Klepser
Jan 31, 2002·The Annals of Pharmacotherapy·Fawziah MarraRobert D Levy
Oct 24, 2001·International Journal of Antimicrobial Agents·M Dutt, G K Khuller
Apr 7, 2009·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Justin A TolmanRobert O Williams

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.